Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
April 29, 2016 7:57 AM EDTBMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $183.00). He notes while results were solid all eyes will be on the upcoming Repatha CV outcomes trial.
Somaiya commented, "AMGN... More
Amgen (AMGN) PT Raised to $186 at Leerink Partners
April 29, 2016 6:58 AM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.
Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More
